INTRODUCTION
============

Although the incidence of rheumatic valvular heart disease is decreasing in Korea, mitral stenosis (MS) is still an important cause of valvular heart disease. Percutaneous mitral balloon valvuloplasty (PMV) has become an effective and safe procedure for symptomatic or hemodynamically significant MS with favorable valve anatomy since its first introduction.[@B1][@B2][@B3] Recent guidelines recommend PMV as the first therapeutic option for hemodynamically significant or symptomatic MS when mitral valve (MV) morphology favors PMV.[@B4] While recent studies have reported long-term (≥10 year) outcomes of PMV, these studies analyzed a predominantly Caucasian population.[@B5][@B6][@B7][@B8][@B9][@B10][@B11][@B12] Although previous studies have shown that echocardiographic scores based on valve morphology correlate with immediate clinical outcomes, these scores do not predict long-term clinical outcomes.[@B13] Thus, recent studies have focused on identifying long-term predictive factors, including hemodynamic, clinical, and/or echocardiographic characteristics. However, most of these studies are based on predominantly Caucasian populations and have relatively limited follow up durations (≤10 years).[@B7][@B14] Moreover, Asian patients tend to be younger than those in Western countries; therefore, long-term clinical outcomes in Asian populations must be investigated as a distinct subgroup.

The aim of this study was to analyze the long-term results (≥20 years) of PMV at a single center. In addition, we determined the predictive factors of late clinical outcomes after successful PMV.

MATERIALS AND METHODS
=====================

Study population
----------------

Between August 1980 and May 2013, 1187 patients underwent PMV at Severance Hospital, Seoul, Korea (Baseline characteristics of 1187 patients are described at [Supplementary Table 1](#S1){ref-type="supplementary-material"}, only online). Of these patients, we retrospectively analyzed those who had regular follow up visits for more than 10 years (n=742). Clinical status was determined by the New York Heart Assocation classification system. The indications of PMV were as follows: symptomatic moderate/severe MS with favorable valve morphology, asymptomatic moderate/severe MS with pulmonary hypertension and favorable valve morphology, and symptomatic moderate/severe MS with unfavorable valve morphology and unable/refused to undergo surgery. This study was approved by the Institutional Review Board of our institute (IRB No: 2013-2099-001).

Techniques
----------

All procedures were performed via the anterograde transvenous approach by experienced physicians. The Inoue balloon technique or the double-balloon technique was used.[@B15] The effective balloon-dilating area was calculated using standard geometric formulas and normalized to body surface area as previously described.[@B16] The procedure was considered effective when full expansion of the balloon was accompanied by improvement in the mitral pressure gradient without detection of significant mitral regurgitation (MR) or any other mechanical complication.[@B16] Optimal PMV results were defined as mitral valve area (MVA) ≥1.5 cm^2^ with MR ≤GII/IV;[@B1][@B3] suboptimal results were defined as MVA \<1.5 cm^2^.[@B2][@B14][@B17]

Echocardiographic evaluation
----------------------------

Comprehensive 2-dimensional transthoracic echocardiograhy (TTE) was performed in all patients before PMV and within 48 hours after PMV. The total echocardiographic score was obtained as previously described by adding the scores of the following morphological features: leaflet mobility, thickness, calcification, and subvalvular lesions using Wilikins scores.[@B13] The MVA was measured by direct planimetry of the mitral orifice in a 2-dimensional short axis view early in diastole and also by the pressure half-time method.[@B18][@B19] Continous wave Doppler was used to calculate the mitral gradient and the peak prespressure gradient of tricuspid regurgitation (TR).[@B15]

Follow up
---------

Demographic, clinical, and procedural variables were collected retrospectively by medical record review and by telephone contact. Clinical and echocardiographic assessments were carried out 6 months after PMV. Event-free TTE was performed once every 3--5 years. Patients were followed up for a mean duration of 214±50 months after PMV. Restenosis was defined as MVA \<1.5 cm^2^ from follow up TTE. Composite endpoints included repeated MV intervention, stroke, or cardiovascularrelated death. Regarding repeated MV intervention, patients were analyzed with respect to whether they underwent any form of MV intervention, including redo PMV, trido PMV, or MV surgery.

Statistical analysis
--------------------

Continuous variables are expressed as mean±SD, and categorical variables are expressed as percentage. Chi-square analysis was used to compare continuous and categorical variables. Kaplan-Meier estimates were used to determine overall and event-free survival rates. Cox regression hazard analyses were used to identify independent correlates of long-term event-free survival. Additive predictive value was assessed by comparing the global chi-squre values. All analyses were performed using SPSS software version 20 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

Baseline characteristics and immediate PMV outcomes
---------------------------------------------------

The baseline characteristics of the 742 patients are described in [Table 1](#T1){ref-type="table"}. The mean patient age was 41.2±11.1 years, and 75% of the patients were female. Optimal results (MVA ≥1.5 cm^2^ and post MR ≤GII) were obtained in 631 (85%) patients. Post PMV MR \>GII was documented in 58 (8%) patients. After PMV, the mean MVA increased significantly from 0.92 cm^2^ to 1.72 cm^2^ (*p*\<0.001), and the mean diastolic pressure gradient (MDPG) decreased from 9.63 mm Hg to 4.15 mm Hg (*p*\<0.001). Severe MR requring surgery (repair or replacement) was performed in 6 (0.8%) patients, and pericardiocentesis was performed in 5 (0.6%) due to cardiac tamponades. None had mitral annular rupture.

The baseline characteristics of patients who achieved optimal results differed significantly from those who achieved suboptimal results. Specifically, patients with optimal results were significantly younger and had sinus rhythm. Moreover, patients with optimal results had significantly lower echocardiographic score, larger pre MVA, smaller left atrium diameter, and less frequent significant TR (≥GII) ([Fig. 1](#F1){ref-type="fig"}).

Long-term clinical outcomes
---------------------------

All 742 patients underwent regular follow up for more than 10 years. Over a mean follow up duration of 214±50 months, 54 (7.3%) patients undewent redo PMV, and 4 (0.5%) underwent trido-PMV. MV surgery was performed in 248 (33.4%) patients due to progression of MS, and mean time interval to MV surgery was 126±72 months. A total of 33 patients (4.4%) experienced stroke, and 35 (4.7%) patients died from cardiovascularrelated causes. The freedom from composite endpoint rates differed significantly between the optimal result group and suboptimal result group (*p*\<0.001) ([Fig. 2](#F2){ref-type="fig"}). The percentage of freedom from restenosis was 75% at 10 years and 53% at 15 years. The event-free survival rate of the composite endpoints was 75% at 10 years and 43% at 15 years.

A univariate analysis indicated that age (*p*=0.041), pre-procedural atrial fibrillation (*p*\<0.001), echocardiographic score \>8 (*p*\<0.001), post-MVA (*p*\<0.001), post-MR ≥GII (*p*\<0.001), and post-TR ≥GII (*p*\<0.001) were associated with poor long-term clinical outcomes ([Table 2](#T2){ref-type="table"}). Multivariate analysis showed that echocardiographic score \[*p*=0.003, hazard ratio=1.56, 95% confidence interval (CI): 1.01--2.41\] and post-MVA (*p*\<0.001, relative risk=0.39, 95% CI: 0.37--0.69) were significant predictors of long-term clinical outcomes after adjusting for confounding variables. A post-MVA cut-off value of 1.76 cm^2^ showed statistically significant predictive power for poor longterm clinical outcomes \[area under curve (AUC): 0.63, 95% CI: 0.59--0.67, sensitivity: 66%, specificity: 56%, *p*\<0.001\]. Preoperative clinical parameters (age, pre-atrial fibrillation), echocardiographic score \>8, and post-MVA showed significant additive predictive value for poor long-term clinical outcomes ([Fig. 3](#F3){ref-type="fig"}).

DISCUSSION
==========

This study showed the long-term (up to 20 years) clinical outcomes of patients who underwent PMV. An echocardiographic score \>8 and post-MVA were significant predictors of poor long-term clinical outcomes. Up to now, only a few studies have reported long-term event-free survival rates. Previously reported 10-year event-free survival rates ranged from 61--88%,[@B5][@B7][@B20] similar to our findings: Our result is in good agreement with previous studies regarding satisfactory 10-year and 15-year event-free survival rates. The rate of reintervention of MV, including redo/trido or MV surgery, over up to 20 years of follow up was 38%.

We found that an echocardiographic score \>8 and post-MVA were independent predictors of long-term clinical outcomes after adjusting for confounding factors. In addition, they showed significant additive predictive value for predicting long-term clinical outcome in a consecutive manner. Favorable valve morphology, reflected by an echocardiographic score ≤8, is known to be critical for optimal immediate results and event-free survival.[@B13][@B21][@B22] Although patients with high echocardiographic score (\>8) tend to have suboptimal results, however, others have suggested that suboptimal results are not necessarily associated with poor long-term clinical outcomes.[@B23] A few studies have suggested that long-term clinical outcomes are independent of echocardiographic scores.[@B24][@B25] Our results showed that preprocedural echocardiographic score is an independent predictor of poor clinical outcomes after adjusting for confounding factors. Specifically, patients with suboptimal results had higher echocardiographic scores and showed significantly poorer long-term clinical outcomes compared to patients with optimal results.

Post-MVA was also an independent predictor of long-term clinical outcomes. In particular, post-MVA ≤1.76 cm^2^ showed statistically predictive value for predicting poor long-term clinical outcomes (AUC: 0.63, 95% CI: 0.587--0.672, sensitivity: 66%, specificity: 56%, *p*\<0.001). Among our cohort, 250 patients (34%) had post-MVA ≤1.76 cm^2^. However, discriminatory power was not very powerful. This finding is similar to those of previous mid-term follow-up studies. Song, et al.[@B25] suggested that post-MVA ≥1.9 cm^2^ was a good negative predictor for poor clinical outcomes with AUC value of 0.63 (sensitivity 72%, specificity 58%, *p*\<0.001). The modest discriminatory power of post-MVA for long-term clinical outcome after PMV could be explained by numerous other factors, such as commissural MR or atrial fibrillation.

Pre-MVA was not significantly associated with long-term clinical outcomes. Although patients with optimal results had significantly larger pre-MVA than those with suboptimal results, pre-MVA was not significantly associated with long-term clinical outcomes. However, younger patients (aged \<50 years) with pre-MVA ≤1.0 cm^2^ had significantly worse event-free long-term clinical outcomes (*p*=0.030) than those with pre-MVA 1.0--1.5 cm^2^ ([Supplementary Fig. 1](#S2){ref-type="supplementary-material"}, only online). This finding may reflect current trends of preferring PMV over MV surgery with mechanical valve, even with unfavorable valve morphology, when MV intervention is indicated in younger patients.

Bouleti, et al.[@B12] suggested that older patients (aged ≥50 years) have significantly increased risk for surgery after PMV (57.3% vs. 32.3%, *p*\<0.001). Our findings are consistent with these results. Specifically, the event-free survival rate was significantly better in younger patients (aged \<50 years) than older patients (aged ≥50 years, *p*\<0.001). Although the univariate analysis in the current study showed that age was a significant predictor (*p*=0.041) of long-term clinical outcomes, it was not, however, a significant predictor in the multivariate analysis.

Some studies have also reported that significant post-MR (≥GII) is a strong predictor of event-free survival.[@B26] However, we found that significant post-MR (≥GII) was not an independent predictor of long-term clinical outcomes. Thus, severity alone does not reflect the influence of post-MR on long-term clinical outcomes after PMV. The mechanism of MR should be taken into consideration. After PMV, such mechanisms can be classified into commisural and non-commisural MR.[@B27] Commisural MR is thought to be the most frequent type of MR after PMV. This type is caused by splits in fused commisures, which are often considered clinically not important.[@B27] However, non-commisural MR is caused by subvalvular damage that leads to chordae rupture or leaflet tearing, which could result in poor prognosis.[@B26] In fact, some studies have reported that the clinical outcomes of PMV differ depending on the mechanism of post-MR.[@B26][@B27] Kim, et al.[@B26] demonstrated that non-commisural MR was a useful predictor for determining poor longterm clinical outcomes (mean follow up \>7 years) among patients with atrial fibrillation and higher MDPG. Unfortunately, the retrospective nature of our study limited the assessment of the mechanism of MR, which could explain non-significant association between post-MR ≥GII and long-term clinical outcomes.

Limitations
-----------

Because of the observational nature of the study, a cause-and-effect relationship cannot be conclusively established between the predictors and the long-term outcomes. Moreover, these data were obtained from an Asian population at a single center, both of which should be considered in the interpretation of our data. Additionally, regular long-term follow up was not possible in all patients; therefore, the follow up TTE intervals differed between the patients. Furthermore, since we included only patients who had follow up data for more than 10 years, those with poor compliance might have been excluded. Regarding echocargioraphic parameters, detailed information on valvular calcification, the type of post-MR (commisural vs. non commisural) or 3D measurement of MVA could have yielded additional insight regarding predictors of long-term clinical outcomes. Further studies with novel echocardiographic techniques could shed additional light on such predictors.

Conclusion
----------

This study reported long-term clinical outcomes after PMV in a large cohort of Asian individuals. In this long-term follow up study, an echocardiographic score \>8 and post-MVA were independent predictors of poor long-term clinical outcomes after PMV, including MV reintervention, stroke, and cardiovascular-related death. Post-MVA ≤1.76 cm^2^ showed satisfactory predictive value for predicting poor long-term clinical outcomes.
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SUPPLEMENTARY MATERIALS
=======================

###### Supplementary Table 1

Baseline Characteristics of 1187 Patients Who Underwent PMV from 1980 to 2013

###### Supplementary Fig. 1

Comparisons of event-free survival rates after PMV in younger patients (\<50) between pre-MVA ≤1.0 cm^2^ and pre-MVA 1.0--1.5 cm^2^. PMV, percutaneous mitral balloon valvuloplasty; MVA, mitral valve area.

###### Supplementary Fig. 2

Long-term clinical outcome of PMV according to pre-procedural indications. Group 1, symptomatic moderate or severe MS with favorable valve morphology; Group 2, asymptomatic moderate or severe MS with pulmonary hypertension and favorable valve morphology; Group 3, symptomatic moderate or severe MS with unfavorable valve morphology but refused to undergo surgery. MS, mitral stenosis.

![Comparisons of pre-PMV echocardiographic score, MVA, LA AP diameter, and significant TR (≥GII) between patients with optimal and suboptimal PMV results. PMV, percutaneous mitral ballon valvuloplasty; MVA, mitral valve area; LA, left atrium; AP, anterior-posterior; TR, tricuspid regurgitation.](ymj-59-273-g001){#F1}

![Kaplan-Meier analysis of event-free survival rates for patients with optimal results after PMV and patients with suboptimal results after PMV. PMV, percutaneous mitral balloon valvuloplasty.](ymj-59-273-g002){#F2}

![Additive predictive value of echocardiographic score \>8 and post-PMV mitral valve area (post-MVA) to baseline clinical parameters for predicting long-term clinical outcomes. ^\*^Age, atrial fibrillation. MVA, mitral valve area; PMV, percutaneous mitral balloon valvuloplasty.](ymj-59-273-g003){#F3}

###### Baseline Characteristics

![](ymj-59-273-i001)

  Variables                             Optimal (n=631)   Suboptimal (n=111)   *p* value
  ------------------------------------- ----------------- -------------------- -----------
  Clinical characteristics                                                     
   Age (yr)                             41±11             44±11                0.006
   Women, n (%)                         473 (75)          83 (75)              0.525
   NYHA classification ≥III, n (%)      331 (53)          52 (43)              0.303
   Atrial fibrillation, n (%)           238 (44)          66 (59)              \<0.001
   Pre-OMC history, n (%)               28 (6)            7 (8)                0.473
  Echocardiographic parameters                                                 
   Echocardiographic score              7.8±1.2           8.4±1.4              \<0.001
   Echocardiographic score \>8, n (%)   88 (14)           29 (26)              0.003
   Pre-MVA, cm^2^ (2D planimetry)       0.94±0.31         0.81±0.38            \<0.001
   LV end diastolic dimension (mm)      48±8              50±8                 0.066
   LV end systolic dimension (mm)       36±8              38±9                 0.054
   Pre MDPG (mm Hg)                     8.8±5.3           9.6±6.2              0.302
   LV ejection fraction (%)             62±9              69±20                0.002
   LAAP diameter (mm)                   51±8              55±12                0.002
   TR≥GII, n (%)                        94 (15)           45 (41)              \<0.001

NYHA, New York Heart Association; OMC, open mitral commissurotomy; MVA, mitral valve area; 2D, two-dimensional; LV, left ventricle; MDPG, mean diastolic pressure gradient; LA, left atrium; AP, anterior-posterior; TR, tricuspid regurgitation.

###### Predictors of Long-Term Clinical Outcomes after Percutaneous Mitral Balloon Valvuloplasty.

![](ymj-59-273-i002)

  Variables                     Univariate   Multivariate                                  
  ----------------------------- ------------ -------------- --------- ------ ------------- ---------
  Age                           1.02         1.01--1.03     0.041     1.01   0.99--1.02    0.303
  Female                        1.42         0.81--2.51     0.072     0.85   0.63--1.15    0.289
  History of OMC                1.94         0.97--3.91     0.061                          
  Atrial fibrillation           1.97         1.51--2.57     \<0.001   1.58   0.94--1.61    0.144
  Echocardiographic score \>8   1.99         1.34--2.97     \<0.001   1.56   1.01--2.41    0.003
  Pre TR ≥GII                   1.72         1.09--2.90     0.004     1.13   0.70--1.85    0.802
  Pre MVA                       0.99         0.69--1.42     0.972                          
  Post MVA                      0.51         0.37--0.69     \<0.001   0.39   0.27-- 0.57   \<0.001
  Post MR ≥GII                  1.78         1.00--2.01     \<0.001   1.45   1.02--2.05    0.062
  Post TR ≥GII                  7.55         4.50--12.6     \<0.001   7.03   0.58--1.71    0.989

MR, mitral regurgitation; MVA, mitral valve area; OMC, open mitral commissurotomy; TR, tricuspid regurgitation.
